Table 4.
The 5-year overall survival according to risk group as defined by prognostic models for all patients and early-stage patients in the validation cohort.
| Risk group | All | Early stage | ||
|---|---|---|---|---|
| % (95% CI) | P | % (95% CI) | P | |
| NRI | <0.001 | <0.001 | ||
| Low | 85.4 (80.9–89.9) | 85.4 (80.9–89.9) | ||
| Intermediate low | 78.7 (74.0–83.4) | 78.7 (74.0–83.4) | ||
| Intermediate high | 68.4 (63.1–73.7) | 69.5 (64.2–74.8) | ||
| High | 52.5 (44.7–60.3) | 56.3 (47.9–64.7) | ||
| Very high | 33.2 (23.6–42.8) | – | ||
| Ann Arbor stage | <0.001 | <0.001 | ||
| I | 78.9 (75.6–82.2) | 78.9 (75.6–82.2) | ||
| II | 67.8 (62.9–72.7) | 67.8 (62.9–72.7) | ||
| III | 53.3 (37.0–69.6) | – | ||
| IV | 29.7 (19.5–39.9) | – | ||
| IPI | <0.001 | <0.001 | ||
| 0–1 | 75.2 (72.4–77.9) | 76.5 (73.7–79.2) | ||
| 2 | 50.3 (40.7–60.0) | 54.1 (41.5–66.6) | ||
| 3 | 20.7 (7.4–34.0) | 31.3 (1.3–66.2) | ||
| 4–5 | 0 | – | ||
| KPI | <0.001 | <0.001 | ||
| Group 1 | 82.3 (78.4–86.2) | 82.3 (78.4–86.2) | ||
| Group 2 | 73.0 (68.5–77.5) | 74.5 (70.0–79.0) | ||
| Group 3 | 62.2 (56.1–68.3) | 66.1 (59.6–72.6) | ||
| Group 4 | 43.8 (35.6–52.0) | 62.4 (50.4–74.4) | ||
| PINK | <0.001 | <0.001 | ||
| Low risk | 77.8 (74.9–80.7) | 77.8 (74.9–80.7) | ||
| Intermediate risk | 59.1 (52.6–65.6) | 63.9 (56.6–71.2) | ||
| High risk | 38.1 (28.1–48.1) | 67.5 (45.9–89.1) | ||
NRI nomogram-revised risk index, IPI International Prognostic Index, KPI Korean Prognostic Index, PINK prognostic index of natural killer lymphoma.